PUT - SPRINTER OPEN END - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 16:02:47 18/06/2024 BST | ||
| 10.17 EUR | -1.36% |
|
| Current month | -39.50% | ||
| 1 month | -50.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 18/06/24 | 10.17 | -1.36% |
| 17/06/24 | 10.31 | -8.68% |
| 14/06/24 | 11.29 | +0.09% |
| 13/06/24 | 11.28 | -10.33% |
| 12/06/24 | 12.58 | -1.41% |
Real-time Boerse Frankfurt Warrants
Last update June 18, 2024 at 04:02 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD1JH9 |
| ISIN | DE000VD1JH97 |
| Date issued | 05/03/2024 |
| Strike | 997.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 19.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.62 € |
|---|---|
| Lowest since issue | 10.17 € |
| Spread | 0.03 € |
| Spread % | 0.30% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
885
USD
Average target price
855.4
USD
Spread / Average Target
-3.35%
- Stock Market
- Certificates
- Certificat